Prosecution Insights
Last updated: November 12, 2026

UNICHEM LABORATORIES LIMITED

Technology area: Biotechnology & Pharmaceuticals

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready

Analysis

UNICHEM LABORATORIES LIMITED has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 3 distinct examiners and 3 distinct art units, indicating separate examination paths across the active portfolio.

REYNOLDS, FRED H is the busiest examiner, with 1 pending matter. Counsel should coordinate the docket centrally while developing examiner- and art-unit-specific responses.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

3
Total Pending OAs
1
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (67%)
1
Easy (33%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§102 only1 (33%)
§112 only1 (33%)
Double-patenting + other1 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
REYNOLDS, FRED H 1 33.2% +39.7%
DICKENS, AMELIA NICOLE 1 47.7% +22.5%
SCHWECHTER, BRANDON ROSS 1 0.0% +0.0%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18260404 LECTIN PROTEIN FOR TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES SCHWECHTER, BRANDON ROSS —

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18691412 RECOMBINANT GLYCAN BINDING PROTEINS AND ITS USE DICKENS, AMELIA NICOLE 25d overdue
18718862 RECOMBINANT PROTEIN FOR SARS-COV2 DISEASE REYNOLDS, FRED H —

Top Art Units

Art UnitApps
1658 1
1645 1
1674 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18718862 RECOMBINANT PROTEIN FOR SARS-COV2 DISEASE REYNOLDS, FRED H 1658 §102§112DP Non-Final OA — Pending Jun 12, 2024
18691412 RECOMBINANT GLYCAN BINDING PROTEINS AND ITS USE DICKENS, AMELIA NICOLE 1645 §102Other Final Rejection 25d overdue Pending Mar 12, 2024
18260404 LECTIN PROTEIN FOR TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES SCHWECHTER, BRANDON ROSS 1674 §112 Final Rejection — Pending Jul 05, 2023

Managing UNICHEM LABORATORIES LIMITED's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does UNICHEM LABORATORIES LIMITED have?

UNICHEM LABORATORIES LIMITED has 3 pending office actions as of November 2026, spread across 3 art units and 3 examiners.

Which USPTO examiner handles the most UNICHEM LABORATORIES LIMITED applications?

Fred H Reynolds has the most, with 1 of UNICHEM LABORATORIES LIMITED's pending office actions.

What technology area are UNICHEM LABORATORIES LIMITED's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month